36,052 Shares in Cassava Sciences, Inc. (NASDAQ:SAVA) Bought by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 36,052 shares of the company’s stock, valued at approximately $10,610,000. International Assets Investment Management LLC owned about 0.08% of Cassava Sciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of SAVA. EntryPoint Capital LLC boosted its position in shares of Cassava Sciences by 1,251.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,297 shares of the company’s stock worth $47,000 after acquiring an additional 2,127 shares in the last quarter. Creative Planning bought a new stake in shares of Cassava Sciences in the third quarter worth $201,000. McAdam LLC bought a new stake in shares of Cassava Sciences in the third quarter worth $208,000. CANADA LIFE ASSURANCE Co grew its stake in shares of Cassava Sciences by 146.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company’s stock worth $191,000 after purchasing an additional 5,594 shares during the last quarter. Finally, NBC Securities Inc. grew its stake in shares of Cassava Sciences by 26.1% in the third quarter. NBC Securities Inc. now owns 9,650 shares of the company’s stock worth $283,000 after purchasing an additional 2,000 shares during the last quarter. 38.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SAVA has been the topic of several analyst reports. HC Wainwright raised shares of Cassava Sciences from a “neutral” rating to a “buy” rating and set a $116.00 price objective on the stock in a research note on Tuesday, October 8th. Rodman & Renshaw restated a “buy” rating and issued a $107.00 target price on shares of Cassava Sciences in a report on Thursday, August 8th.

Cassava Sciences Stock Down 2.0 %

SAVA stock opened at $26.00 on Thursday. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -11.98 and a beta of -0.63. Cassava Sciences, Inc. has a 12-month low of $8.79 and a 12-month high of $42.20. The company’s fifty day simple moving average is $28.17 and its 200 day simple moving average is $22.77.

Cassava Sciences (NASDAQ:SAVA) last released its earnings results on Thursday, August 8th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.57. During the same quarter last year, the business posted ($0.63) earnings per share. Research analysts expect that Cassava Sciences, Inc. will post -5.7 earnings per share for the current year.

Cassava Sciences Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.